Navigation Links
Osteoporosis in Biological Technology

Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)

... monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and ... to patients worldwide who are afflicted by osteoporosis and other bone loss conditions. "Our ... benefit and value to patients with postmenopausal osteoporosis and other bone disease conditions. Together ...

Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August

... for prevention and treatment of postmenopausal osteoporosis and prevention and treatment of bone loss in ... fracture in her remaining lifetime. Although osteoporosis treatments are available, there remains a need ... 3 pivotal studies with fracture endpoints, in the osteoporosis and prostate cancer settings, demonstrated ...

FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab

... are treatment and prevention of postmenopausal osteoporosis (PMO) in women and treatment and prevention of ... Often referred to as the "silent epidemic," osteoporosis is a global problem that is increasing in ... Health Organization (WHO) has recently identified osteoporosis as a priority health issue along with other major ...

deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis

... accounting for a sufficient proportion of risk of osteoporosis to develop a clinically useful DNA-based risk ... by early adulthood. Those at high risk of osteoporosis could therefore take concrete measures including ... risk Factor (PERF) study and the Australian Dubbo osteoporosis Epidemiological Study (DOES), for making this ...

Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics

... present new research findings on the genetics of osteoporosis at the 58th Annual Meeting of the American ... Fracture (SOF), multi-center study on osteoporosis and aging in women greater than or equal to age ... About Osteoporosis According to the National osteoporosis ...

Osteoporosis Drugs Increase Risk for Heart Problems

... Irregular Heartbeat Is Side Effect of Common osteoporosis Medications PHILADELPHIA, Oct. 27 /PRNewswire/ -- People who take bisphosphonates for osteoporosis may be at risk for serious atrial fibrillation ... 100 percent were women using bisphosphonates for osteoporosis with a mean age range 69 to 75 years. Patients in ...

HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City

... as heart disease, stroke, arterial disease, and osteoporosis long before any symptoms are present -- ... offering the Arterial Stiffness Index. -- osteoporosis Screening -- A bone densitometer provides a ... as well as fracture risk and skeletal strength. osteoporosis is a disease in which bones become fragile and ...

Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures

... -- Results from the Global Longitudinal study of osteoporosis in Women (GLOW) showed that 55 percent of women diagnosed with osteoporosis do not believe they are at a higher risk ... potentially impact their lives." By definition, osteoporosis causes bones to become fragile and therefore more ...

Global Study Reveals Differences in Standard of Care for Osteoporosis Across the World

... the Global Longitudinal Registry of osteoporosis in Women (GLOW), which will monitor the health of ... and multiple therapeutic options being available, osteoporosis remains largely under-diagnosed ... Australia. GLOW will gather information on osteoporosis risk factors, treatment approaches, patient ...

Stonegate Report About Unigene Laboratories Inc.

... a sCT-based product that addresses the osteoporosis market, in 2005. Upsher-Smith Laboratories ... million range. - Safety concerns in the osteoporosis market - Bisphosphonate-based therapies, the leaders in the $7 billion osteoporosis market, have come under scrutiny following ...

Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor

... associated in the development of osteoporosis or cardiovascular disease - North American ... of genetic risk assessment tests in the field of osteoporosis and cardiovascular disease in new populations as ... About Osteoporosis According to the National osteoporosis ...

Cooler Solutions and Leading Research Hospital to Design Revolutionary Osteoporosis Diagnosis Device

... at risk of losing bone mass during space flight. osteoporosis is a serious disease characterized by low bone ... in 3 women and 1 in 5 men over the age of 50 have osteoporosis worldwide. Working together with key ... with the potential to revolutionize the osteoporosis diagnostic area. We are working towards a day ...

Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis

... all formulations of BA058, Radius' osteoporosis drug candidate. BA058 is a proprietary analog of ... of BA058 to address important unmet needs for osteoporosis patients in the near future, and in the ... in Phase II clinical trials for the treatment of osteoporosis in postmenopausal women. BA058 is designed to ...

Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis

... a full year's protection against the effects of osteoporosis -- a disorder that causes bones to break easily. ... patients a choice when it comes to taking their osteoporosis therapy." Reclast/Aclasta is approved in more ... is recommended that patients with postmenopausal osteoporosis take calcium and vitamin D supplements, ...

Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development

... field of endocrinology, where he has direct experience with diabetes and osteoporosis indications. Prior to joining Halozyme, Dr. Muchmore served as Medical ... insulin program, Dr. Muchmore served on the Evista Product Team for osteoporosis and breast cancer indications from 1995 to 1999 and as its Physician Group ...

Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO

... Surgery and New York Hospital, where she focused on metabolic bone and osteoporosis diseases. Stephen Worsley, vice president, business development has held ... patch formulation versus injectable Forteo in 165 women with severe osteoporosis in multiple sites across North and South America. Top line results from ...

Barr Launches Generic Fosamax(R) Tablets, 70 mg

... Sodium product is indicated for the treatment and prevention of osteoporosis in postmenopausal women; for the treatment to increase bone mass in men with osteoporosis; for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to ...

Hologic Announces First Quarter Fiscal 2008 Operating Results

... a part of Cytyc) operations are now included in Breast Health, and the osteoporosis assessment, mini C-arm and MRI products are included in Skeletal Health. ... breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, and mini C-arm for extremity ...

Ralf Rosskamp, M.D. Joins Biodel's Scientific Advisory Board

... contribute to the development of VIAject(TM), VIAtab(TM) and our two osteoporosis product candidates." "I am delighted to join Biodel's SAB, especially at ... tablet formulation of insulin in Phase I clinical trials and two osteoporosis product candidates in pre-clinical studies. For further information ...

Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors

... union of the bone due to the extreme severity of the fracture or because the patient is medically impaired due to an illness such as diabetes or osteoporosis or life style choices such as smoking. These non-healing fractures, known as non-union fractures, are costly and debilitating. Aging is another ...

NCIIA Honors Top Collegiate Biomedical Engineering Teams

... on a biosensor to detect vitamin D levels. Although current research suggests that vitamin D deficiency can lead to health problems including osteoporosis and cancer, it is currently difficult to measure these levels accurately. The Brown team has developed a rapid method of diagnosing these with a ...

Simcere Pharmaceutical Group to Announce 2009 First Quarter Earnings on Monday, May 18, 2009

... diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com . ...

Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences

... to 135,000 and reinforce the core strengths in key public health areas such as cancer, cardiovascular disease, diabetes, obstructive lung disease, osteoporosis and mental health. More than 60 % of the participants have been screened twice, 25 % have participated in all three surveys. "For both ...

Magellan to Receive Frost & Sullivan 2009 North American Product Innovation Award; Three-Minute LeadCare(R) II Test Identifies Children with Lead Poisoning

... blood-lead levels and lowered IQ, behavior and learning problems, increased drug abuse and crime, and adult health problems -- from dental decay and osteoporosis to cardiovascular disease, stroke, and even early cognitive deterioration associated with aging. Studies also show that infants and toddlers exposed ...

Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55

... an investigational RANK Ligand inhibitor. The indications for which Amgen is seeking FDA approval are treatment and prevention of postmenopausal osteoporosis (PMO) in women, and treatment and prevention of bone loss in patients undergoing hormone ablation for either prostate or breast cancer. The BLA ...

AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers

... peri- and postmenopausal phases, baby-boomers and seniors needing extra calcium supplementation. "The role of calcium in the pathogenesis of osteoporosis is significantly prominent. There is insufficient intake of dietary calcium and minerals in our diet, particularly in those with an active lifestyle. ...

Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings

... diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit ...

Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform

... of specific tissue effect. "Selective estrogen modulators (SERMs) are an exciting class of drugs that are used to prevent breast cancer and osteoporosis and differ from estrogens in how they regulate gene transcription," said Dr. Dale Leitman, from the Department of Obstetrics, Gynecology and ...

Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008

... diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit ...

Amgen Positioned to Deliver Attractive Growth Over Next Five Years

... in the first half of 2009. Amgen expects to complete its Biologic License Application (BLA) data package for denosumab for post menopausal osteoporosis by the end of 2008 or early 2009. Amgen looks forward to working in due course with regulatory authorities and governments worldwide to secure ...

Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase

... diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit ...

Gerson Lehrman Group and BIO Collaborate to Identify Scientific Expertise for the Seventh Annual BIO Investor Forum

... Failure -- Cystic Fibrosis -- Epilepsy -- Fibromyalgia -- Lung Cancer -- Neurodegenerative Diseases -- Novel Solid Tumor Targets -- osteoporosis -- Pre-ASH Primer "With the financial markets experiencing an unprecedented level of volatility, investment professionals place a greater premium ...

Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008

... diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com . ...

Vista Partners Updates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx), Raises Target Price to AU$1.65

... The pipeline consists of four lead drug programs: ART621 to treat severe rheumatoid arthritis and other inflammatory diseases; ART010 to treat osteoporosis and bone cancer; ART104 to treat solid tumours in colorectal cancer; and ART150 for lung cancer and melanoma. Additionally the company has earlier ...

Retrospective Analysis of Phase 3 Data Suggest Wyeth's Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms

... with Wyeth's investigational compound bazedoxifene (BZA) alone did not appear to increase mammographic breast density in postmenopausal women with osteoporosis compared to raloxifene (the active comparator) or placebo over two years. BZA is an investigational selective estrogen receptor modulator (SERM) ...

Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources

... diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit ...

Hologic to Present at the Morgan Stanley Global Healthcare Unplugged Conference

... for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, and mini C-arm for extremity imaging. For more information visit http://www.hologic.com . Contact: ...

Renowned NJ-Based Video Assisted Thoracic Surgery (VATS) Team Completes 5,000th Successful Procedure

... Bocage, M.D., Thoracic Group, P.A. surgeon. "There are a number of co-existing or debilitating conditions such as cardiac disease, diabetes or osteoporosis that can prohibit traditional open surgery. What we want to communicate is that VATS allows thoracic surgery patients to return to their normal life ...

Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.

... for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, and mini C-arm for extremity imaging. For more information visit http://www.hologic.com . About Third ...

Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period

... for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, and mini C-arm for extremity imaging. For more information visit http://www.hologic.com . About Third ...
Other Contents
(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
(Date:10/14/2014)... new study published in Cancer Research shows ... and colon cancers—can promote the development of skin cancers ... and survival of sun-damaged skin cells. , Previously considered ... proteins called sirtuins that help regulate genomic stability and ... SIRT6 helps repair DNA damage, which can lead to ...
(Date:10/14/2014)... how to produce enough food to feed the world ... Organization of the United Nations predicts that food production ... feed a growing global population, and plants are one ... Plants—grains, cereals, fruits, vegetables, and more—feed humans directly ... tap into our knowledge of how plants work to ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
(Date:10/22/2014)... 2014 Shriners Hospitals for Children® and ... the current location of Shriners Hospitals for Children - ... from the University of Kentucky Albert B. Chandler Hospital. ... center, owned and operated by Shriners Hospitals for Children, ... children and their families well into the future. , ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... Richard Carlson, Managing Partner of Blue ... over 25 years experience. Mr. Carlson is a ... related to EDI, B2B Commerce, RFID and Internet/Intranet technology. ... Board member for Pharmaceutical Commerce Magazine and a Gerson ... is a management and technology consulting firm focused solely ...
(Date:10/22/2014)... Tara Haelle HealthDay ... Binge drinking among young adult men may lead to increased ... drinking didn,t cause a similar rise in blood pressure for ... In fact, when young adult women drank lightly or moderately, ... the study found. "This finding parallels studies in older ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 The ... the must-have source of thousands of facts, figures and ... countries and 68 medical sector forecast categories the ... with global, regional and national views on the worldwide ... outlook. , The report gives you data for 2010-2019, ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4
Other TagsOther Tags